8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2, 2013

Shire plc

_________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

_________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

_________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

_________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.      Other Events

Shire plc has issued the press releases attached hereto as Exhibit 99.01, Exhibit 99.02 and Exhibit 99.03 which are incorporated by reference herein.

Item 9.01.      Financial Statements and Exhibits

(d)  Exhibits.  The following exhibits are filed herewith:

99.01           Press Release dated April 2, 2013

99.02           Press Release dated April 2, 2013

99.03           Press Release dated April 2, 2013

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name:Angus Russell
	Title:Chief Executive Officer

Dated: April 2, 2013

EXHIBIT INDEX
Number	Description
99.01	Press release dated April 2, 2013
99.02	Press release dated April 2, 2013
99.03	Press release dated April 2, 2013

EX-99.1

Exhibit 99.01

Press Release www.shire.com

Director/PDMR Share Dealings

April 2, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG), (the “Company”) announces that on March 28, 2013 Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) of the Company, as set out below, had been acquired for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from January 1 to March 31, 2013.

	Type of Security (1)	Number of Shares/ADSs
William Burns	Shares	255
Dr. Steven Gillis	ADSs	80
Dr. David Ginsburg	ADSs	73
David Kappler	Shares	302
Susan Kilsby	ADSs	75
Anne Minto	Shares	266
David Stout	ADSs	81

(1)              One ADS is equal to three Shares

The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively, at prices of £19.90 per Share and $90.00 per ADS.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients’ needs, we develop and provide healthcare in the areas of:

· Behavioral Health and Gastro Intestinal conditions

· Rare Diseases

· Regenerative Medicine

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

2

EX-99.2

Exhibit 99.02

Press Release www.shire.com

Total Voting Rights

April 2, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with DTR 5.6.1 of the FSA’s Disclosure and Transparency Rules, notifies the market of the following:

At close of business on April 1, 2013, the Company’s issued ordinary share capital comprised 556,799,122 ordinary shares of 5 pence each with voting rights and a further 6,007,188 ordinary shares held in treasury.

Therefore the total number of voting rights in the Company is 556,799,122.  This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients’ needs, we develop and provide healthcare in the areas of:

· Behavioral Health and Gastro Intestinal conditions

· Rare Diseases

· Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

EX-99.3

Exhibit 99.03

Press Release www.shire.com

Director/PDMR Share Dealings

April 2, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG), (the “Company”) announces that it was notified on March 28, 2013 that on the same day the Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) of the Company, as set out below, had been awarded under the Shire Executive Annual Incentive Plan (“EAIP”) to Persons Discharging Managerial Responsibility (“PDMRs”). The Shares and ADSs were acquired on March 28, 2013 at prices of £19.94 per Share and $90.00 per ADS.

	Type of Security	Number of Shares/ADSs
Angus Russell (Chief Executive Officer)	ADSs	3,123
Graham Hetherington (Chief Financial Officer)	Shares	4,504
Sylvie Gregoire	ADSs	1,262
Jeffrey Jonas	ADSs	932
Tatjana May	Shares	2,702

The awards will normally be released to participants after a period of three years.  One ADS is equal to three Shares.

In addition, the Company was notified on April 2, 2013 of the release of the following ADSs and Shares awarded in 2010 under the EAIP.

	Type of Security	Number of Shares/ADSs released	Number of Shares/ADSs sold to satisfy tax liabilities
Angus Russell (Chief Executive Officer)	ADSs	7,421	6,176
Graham Hetherington (Chief Financial Officer)	Shares	12,569	6,552
Tatjana May	Shares	7,515	3,918

On April 1 and April 2, 2013, sufficient ADSs and Shares were sold respectively, to satisfy tax liabilities as set out above. The ADSs and Shares were sold at prices of $90.9568 per ADS and £19.94 per Share.

The above transactions in Shares and ADSs took place on the London Stock Exchange and NASDAQ respectively.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Eric Rojas	erojas@shire.com	+1 781 482 0999
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients’ needs, we develop and provide healthcare in the areas of:

· Behavioral Health and Gastro Intestinal conditions

· Rare Diseases

· Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

2